10-QPeriod: Q3 FY2024

DEXCOM INC Quarterly Report for Q3 Ended Sep 30, 2024

Filed October 24, 2024For Securities:DXCM

Summary

DexCom, Inc. (DXCM) reported its financial results for the quarter and nine months ended September 30, 2024. Revenue for the third quarter increased by 2% year-over-year to $994.2 million, and by 13% for the nine-month period to $2,919.5 million. While revenue showed growth, gross profit saw a slight decrease of 5% in the third quarter to $593.8 million, attributed to product and channel mix changes and a non-cash inventory charge. Net income for the third quarter increased by 12% to $134.6 million, resulting in diluted EPS of $0.34. For the nine-month period, net income surged by 49% to $424.5 million, with diluted EPS at $1.04. The company ended the period with a strong liquidity position, including $2.49 billion in cash, cash equivalents, and short-term marketable securities. Operating cash flow for the nine months was robust at $688.1 million. Significant strategic initiatives include the launch of Stelo, a new biosensor for adults with prediabetes and Type 2 diabetes, and continued investment in R&D and international expansion. However, investors should note ongoing patent litigation with Abbott and recent securities class action lawsuits, which introduce considerable uncertainty.

Financial Highlights

51 data points
Beta

Revenue

$994.20M

59.7% Gross Margin

Net Income

$134.60M

13.5% Net Margin

EPS (Diluted)

$0.34

Total Assets

$6.35B

Cash & Equivalents

$621.20M

Free Cash Flow

$88.30M

Financial Statements
Beta
Revenue$994.20M
Cost of Revenue$400.40M
Gross Profit$593.80M
R&D Expenses$135.40M
SG&A Expenses$306.40M
Operating Expenses$441.80M
Operating Income$152.00M
Interest Expense$3.70M
Net Income$134.60M
EPS (Basic)$0.34
EPS (Diluted)$0.34
Shares Outstanding (Basic)394.20M
Shares Outstanding (Diluted)410.20M

Key Highlights

  • 1Revenue for Q3 2024 increased 2% year-over-year to $994.2 million, driven by increased sales volume of disposable sensors.
  • 2Net income for Q3 2024 rose 12% to $134.6 million, with diluted EPS of $0.34.
  • 3Nine-month net income increased significantly by 49% to $424.5 million, reflecting strong operational performance.
  • 4The company maintains a strong liquidity position with $2.49 billion in cash, cash equivalents, and short-term marketable securities as of September 30, 2024.
  • 5Operating cash flow for the first nine months of 2024 was $688.1 million, indicating healthy cash generation.
  • 6Dexcom launched its new Stelo biosensor in August 2024, targeting adults with prediabetes and non-insulin dependent Type 2 diabetes.
  • 7The company faces ongoing patent litigation with Abbott and recently disclosed securities class action lawsuits, which introduce significant legal and financial risks.

Frequently Asked Questions

Revenue growth is primarily driven by increased sales volume of disposable sensors due to the continued expansion of its worldwide customer base. The company added approximately 600,000 net users in 2023.

The decrease in gross profit margin percentage in Q3 2024 compared to Q3 2023 was primarily due to product and channel mix changes, as well as a $24.6 million non-cash inventory build charge.

DexCom maintains a strong liquidity position with $2.49 billion in cash, cash equivalents, and short-term marketable securities as of September 30, 2024. It also generates positive operating cash flow and has access to a $200 million revolving credit facility. The company expects these resources to be sufficient for its short-term and long-term liquidity needs, including capital expenditures and strategic initiatives.

DexCom is involved in ongoing patent litigation with Abbott involving continuous glucose monitoring products. Additionally, several securities class action lawsuits and derivative actions have been filed recently, alleging false and misleading statements and seeking damages for the company. The outcomes of these litigations are uncertain and could materially affect the company's financial condition.